Generics drive Amerisource financials; Facilities planned, completed and approved;

> Big 3 drug distributor Amerisource cites sales of generics as a driver in its higher-than-expected quarterly profit growth. Article [1]

> The FDA has approved Orthovita's facility in Malvern, PA, for collagen processing and the manufacture of collagen-based products. Article [2]

> Novavax has been issued U.S. Patent No. 7,763,450, "Functional Influenza Virus-Like Particles (VLPS)," for the manufacturing process that uses influenza gene sequences for production of vaccines to protect against current and future seasonal and pandemic flu strains. Release [3]

> Meridian Life Science is boosting investment in facilities, equipment and infrastructure to provide R&D support for contract manufacturing and custom biologics development. Release [4]

> ATMI has completed the expansion of its Bloomington, MN, manufacturing facility, the North American hub for production and development of the Integrity single-use technology products. Announcement [5]